1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsTranslational Research in Maternal and Pediatric Pharmacology and Therapeutics (R21 Clinical Trial Optional) is sponsored by National Institute of Child Health and Human Development (NICHD). Supports exploratory research to improve therapeutics for maternal and pediatric populations.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Opportunity Listing - Translational Research in Maternal and Pediatric Pharmacology and Therapeutics (R21 Clinical Trial Optional) Translational Research in Maternal and Pediatric Pharmacology and Therapeutics (R21 Clinical Trial Optional) Agency: National Institutes of Health Assistance Listings: 93. 865 -- Child Health and Human Development Extramural Research 93. 279 -- Drug Use and Addiction Research Programs 93.
855 -- Allergy and Infectious Diseases Research 93. 313 -- NIH Office of Research on Women's Health Last Updated: June 5, 2026 View version history on Grants.
gov The purpose of this notice of funding opportunity (NOFO) is to support translational and clinical research to (1) advance precision medicine in pregnant women, lactating women, and children through the development of novel tools, models, and other technologies that could have a direct clinical or health impact; (2) enhance the understanding of the underlying mechanisms of drug action, including the role of pediatric ontogeny and the dynamic physiological changes that occur during pregnancy and lactation; and (3) discover and develop novel therapeutics or enhance the usage of existing drugs or drug repurposing for safer and more effective medications in pregnant and lactating women, neonates, and children.
The overall goal is to improve safe and effective precision therapeutics for pregnant and lactating women, fetuses, neonates, and children, including those with disabilities.
Nonprofits non-higher education without 501(c)(3) Other Native American tribal organizations Nonprofits non-higher education with 501(c)(3) Public and Indian housing authorities City or township governments Federally recognized Native American tribal governments Special district governments For-profit organizations other than small businesses Public and state institutions of higher education Independent school districts Private institutions of higher education Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Grantor contact information See Section VII. Agency Contacts within the full opportunity announcement for all other inquires. File name Description Last updated PAR-25-111-Full-Announcement.
html PAR-25-111 Full Announcement Text Nov 18, 2024 07:10 PM UTC Link to additional information https://grants. nih. gov/grants/guide/pa-files/PAR-25-111.
html Funding opportunity number : Cost sharing or matching requirement : Funding instrument type : Opportunity Category Explanation : Category of Funding Activity : Income security and social services Your account requires additional identity verification.
According to the current listing, eligibility includes: Nonprofits, Universities, State/local governments, For-profit organizations, Small businesses, Individuals. Confirm the full requirements in the official notice before applying.
The current listing shows up to $275,000 over 2 years. Verify award ceilings, matching requirements, and allowable costs in the official notice.
Translational Research in Maternal and Pediatric Pharmacology and Therapeutics (R21 Clinical Trial Optional) is funded by National Institute of Child Health and Human Development (NICHD). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
NICHD's FY2026 funding strategy applies an automatic 14 percent reduction to every new R01 below the peer-review recommended level, eliminates inflationary increases on future-year commitments, and abandons a fixed payline entirely in favor of priority-driven discretion. The structural implications for child health investigators.
Read articleThe STOMP program funds measurement tools and removal therapies for microplastics in human tissue. Proposals due June 22. Eligibility, phases, and strategy.
Read articleThe Gates Foundation committed at least $1 billion over two years to equitable AI alongside its 10th Goalkeepers Report — 40% education, 40% health, 10% agriculture, 10% digital infrastructure. Five days later, 60 organizations signed a five-year goal to reach 3.4 billion speakers of underrepresented languages. Here is how implementing nonprofits should read both.
Read article